NEW YORK (GenomeWeb News) — GE Healthcare has agreed to license certain of its patents for biomagnetic nucleic-acid isolation to screening and diagnostics company NorDiag, GE Healthcare said yesterday.

 

GE Healthcare said the IP differs from conventional nucleic acid-isolation techniques due to the fact that the increased yield of nucleic acids it can isolate from disease-causing pathogens allows “diagnosis from smaller-volume patient samples.”